

# Elevar Therapeutics Announces Exclusive Global Licensing Agreement with Relay Therapeutics for Lirafugratinib

Client News

December 3, 2024

Gunderson Dettmer represented client Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company, in its exclusive global licensing agreement with Relay Therapeutics, a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, for rights to develop and commercialize lirafugratinib. Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors.

Under the terms of the agreement, Elevar will be granted global development and commercialization rights for lirafugratinib. Elevar will assume full responsibility for all further development activities, including submission of the NDAs, all subsequent clinical development, and global commercialization for FGFR2-driven CCA and FGFR2-altered other solid tumors. Relay Therapeutics is eligible to receive up to \$75 million in upfront and regulatory milestones, plus up to \$425 million in potential commercial milestone payments, as well as tiered royalties up to the low-teens percentage.

In the [announcement of the agreement](#), Elevar Therapeutics chief executive officer Saeho Chong, Ph.D. said, “Lirafugratinib is an NDA-ready therapy that has shown a potential best-in-class profile in both FGFR2-driven cholangiocarcinoma and in other FGFR2-altered solid tumors including in advanced stages where treatment options

are limited. We are excited to diversify and expand our late-stage oncology pipeline with liralumab, which is a strong strategic fit with our existing oncology portfolio and provides another opportunity to advance our mission of bringing life-changing medicines to cancer patients worldwide.”

The Gunderson Dettmer team was led by Tim Ehrlich and included Joel Diamond and Ross Ewing.

## Companies

Elevor Therapeutics

Relay Therapeutics

## Related People



Timothy H. Ehrlich

PARTNER

P +1 617 648 9399



Joel T. Diamond

ASSOCIATE

P +1 617 648 9136





Ross M. Ewing

ASSOCIATE

P +1 617 648 9355

## Related Services

Life Sciences

Life Sciences Licensing & Strategic Partnering

## Featured Insights

### FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

### CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

### CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

### CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

### CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

### CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

### INSIGHTS

## Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

### CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

### INSIGHTS

Client Insight: California AI Transparency Act

### INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

### INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

### CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding